Lilly's migraine med approved in Canada for episodic cluster headache

  • Eli Lilly and Company (LLY -0.5%) has announced that its monoclonal antibody therapy Emgality (galcanezumab) has received approval in Canada as a treatment for episodic cluster headache.
  • It intends to reduce the frequency of attacks throughout a cluster period in adults with prior cluster headache periods lasting at least 6 weeks with an inadequate response/ tolerated poorly/ had contraindications to conventional preventive therapies established by Canadian practice guidelines.
  • The company has run a trial involving 106 adult patients to evaluate the safety and efficacy of Emgality (300 mg once a month).
  • The subcutaneously administered therapy binds calcitonin gene-related peptide to prevent its biological activity.
  • In the U.S. Emgality received the FDA approval for the treatment of adults with episodic cluster headache in 2019 and the prevention of migraine in 2018.

    Expectations Eli Lily

    Over the current book year the company from Indianapolis could achieve a revenue around 27.99 billion USD (consensus estimates). This is hugely more than 2020's revenue of 24.54 billion USD.

    Historical revenues and results Eli Lilly plus estimates 2020

    aandelenanalyseEli Lilly

    The analysts expect for 2021 a net profit of 7.61 billion USD. For this year the consensus of the result per share is a profit of 8.36 USD. The price-earnings-ratio equals 24.51.

    Per share the analysts are expecting a dividend of 3.37 USD per share. Eli Lilly's dividend yield thus equals 1.64 percent. The average dividend yield of the pharmaceutical companies is a limited 0.38 percent.

    Eli Lilly's market capitalization is based on the number of outstanding shares around 196.19 billion USD. The Eli Lilly stock was the past 12 months quite volatile. Since last February the stock is even 66 percent higher. This year the stock price moved between 117 and 218 dollar.

    Historical stock prices Eli Lilly

    historical stocks elililly

    Click here for dividend Eli Lilly. On Friday the stock closed at 204.89 USD.

    Analist.nl Nieuwsdienst: +31 084-0032-842
    nieuws@analist.nl

    Copyright analist.nl B.V.
    All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.